At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 150 enrolled
Drug / intervention
Geltim LP 1 mg/g +1 moredrug
Likely dose
Geltim LP 1 mg/gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy Assessment of Geltim LP® 1 mg/g (Unpreserved Timolol Gel - TG1030) in Ocular Hypertensive or Glaucomatous Patients Stabilized by Xalatan® With Ocular Intolerance Signs.
In Brief
A Phase 4 clinical trial evaluating Geltim LP 1 mg/g and Xalatan for Glaucoma. Completed, enrolled 150 participants across 1 site.
Detailed Summary
This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of Xalatan® with ocular objective signs of intolerance to prostaglandin eye drops.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
Primary CompletionJul 2009
Study CompletionDec 2009
First PostedJul 2010
TodayJul 2026
First PostedJul 1, 2010
Enrollment StartJul 1, 2008
Primary CompletionJul 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.0 years ago
Interventions
Geltim LP 1 mg/gdrug
one drop in the conjunctival sac of each eye in the morning (84 days).
Xalatandrug
one drop in the conjunctival sac of each eye in the morning (84 days).